10 November 2015 by va-design

Journal article 2

A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis

Full list of Authors
Arden NK, Åkermark C, Andersson M, Todman MG, Altman RD

Full AMA reference
Arden NK., Åkermark C., Andersson M., Todman MG., Altman RD. A randomized saline-controlled trial of NASHA hyaluronic acid for knee osteoarthritis. Current Medical Research & Opinion Vol. 2014; 30(2): 279–286.

Study Design
Level-I clinical study: multi-centre, randomized, double-blind, saline-controlled.

Objective
A 6 week saline-controlled study to investigate the safety and efficacy of NASHA® in patients with mild–moderate structural OA confined to the study knee.

Conclusion
218 patients with KL grade II –III OA in a single knee were randomized into two treatment groups (DUROLANE 108, saline 110). No statistically significant difference in responder rate was found between the two groups at 6 weeks (NASHA: 30.6%; saline: 26.4%). A post-hoc subgroup analysis of patients without clinical effusion in the study knee at baseline showed a significantly higher (p=0.0084) 6 week responder rate with NASHA (NASHA: 40.6%; saline: 19.7%).

Click here to view abstract

Summary of Indications for Use
DUROLANE (3mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE SJ (1mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling (1mL / 3mL).

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

© 2019 Bioventus LLC.

^{*First introduced in the European Union in 2001.}

To learn more about DUROLANE or for contact information, please select your location to continue.

Cookie Law

Nosso site usa cookies, alguns dos quais são essenciais para que este site funcione corretamente e já tenha sido definido. Para mais informações sobre como gerenciar, bloquear ou excluir cookies em seu navegador, consulte as referências em nossa Política de Privacidade. Ao utilizar o nosso site, você aceita os termos da nossa política de privacidade.

Definições